Bain Capital Private Equity
Bain Capital Private Equity pioneered the value-added investment approach, partnering with management teams around the world to accelerate growth through strategic and operational transformation. The firm invests across sectors including consumer, healthcare, industrials, services, and technology.
They made 2 investments in the last 12 months. Average disclosed round size is $408.8M (across 17 rounds with reported amounts).
Portfolio
18
Fund Size
$11.8B
Top Stage
Unknown
Last 12 Mo
2
Team
Chris An
Managing Director
Emily Ashworth
Managing Director
Eric Anderson
Managing Director
Nicholas Bendt
Managing Director
Saahil Bhatia
Managing Director
Anthony MinGyu Bae
Partner
James Bath
Operating Partner
John Belitsos
Partner
Luca Bassi
Partner
Maria Andrisani
Partner
Ankit Aggarwal
Principal
Hannah Bend
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| KKailera | Unknown | $625M | Apr 2026 |
| KKailera | Series B | $600M | Oct 2025 |
 Cardurion Pharmaceuticals | Series B | $260M | Jul 2024 |
 Brillio | Unknown | — | Sep 2023 |
 PULSEDATA | Series A | $16.5M | Jan 2021 |
 Linc'well | Series C | $69.7M | May 2019 |
| SSundial Brands | Unknown | — | Sep 2015 |
| DDunkin' Brands | Unknown | $2.6B | Jan 2015 |
 Sealy Corporation | Ipo | $299.2M | Apr 2006 |
| DDunkin' Brands | Unknown | $1.7B | Jan 2006 |
| QQuEST Global Services | Growth | $75M | Jan 2003 |
| PProfitLogic | Unknown | $20M | Jan 2002 |
 GT Bicycles | Ipo | $65.8M | Jan 1995 |
| GT Bicycles | Unknown | $66M | Jan 1993 |
| CCerevel Therapeutics | Unknown | $350M | — |
 Kestra Medical Technologies | Bridge | — | — |
| LLincwell | Series C | $69.7M | — |
 QuVa Pharma | Growth | $41M | — |
 IMCD | Debt | — | — |
 Lilliput | Growth | $86M | — |
| AAmerican Pad & Paper | Unknown | $5.1M | — |
Top Co-Investors
Last updated: 20 October 2026